Diagnosing and treating community-acquired pneumonia—A double-blind study?
Authors:
- 27 June 2025
- journal article
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (2) , 97-100
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021The Lancet Infectious Diseases, 2024
- The host response in different aetiologies of community-acquired pneumoniaEBioMedicine, 2022
- Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsNew England Journal of Medicine, 2021
- Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19Mayo Clinic Proceedings, 2021
- Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19New England Journal of Medicine, 2021
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19New England Journal of Medicine, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- The allocation of US$105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investmentsThe Lancet Global Health, 2020
- Unique cytokine and chemokine patterns in bronchoalveolar lavage are associated with specific causative pathogen among HIV infected patients with pneumonia, in Medellin, ColombiaCytokine, 2015